Linklaters and Baker & McKenzie have won lead roles advising on Novartis’ definitive agreement to divest its influenza vaccines business to Australian biotech firm CSL Limited (CSL), for $275m.
Dealwatch: After GSK deal, Linklaters leads for Novartis on $275m sale of influenza vaccines as Bakers acts for CSL
